All Stories

  1. Residual lung abnormality following COVID-19 hospitalisation is characterised by biomarkers of epithelial injury

    Article • EBioMedicine, February 2026, Elsevier

    Dr dan Wootton

  2. Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Article • The Lancet Infectious Diseases, January 2026, Elsevier

    MD Pilar Rivera Ortega, Alexander Mathioudakis, Dr Fakher Rahim, Dr dan Wootton

  3. Dynamic impact of bivalent COVID-19 vaccine boosters on systemic and mucosal antibody and T cell immunity

    Article • Scientific Reports, November 2025, Springer Science + Business Media

    Dr dan Wootton

  4. Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Article • The Lancet Infectious Diseases, September 2025, Elsevier

    Alexander Mathioudakis, MD Pilar Rivera Ortega, Dr dan Wootton

  5. P236 Are postal sputum samples a valid clinical and research tool for use in cystic fibrosis?

    Article • Journal of Cystic Fibrosis, June 2025, Elsevier

    Dr dan Wootton

  6. Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

    Article • EClinicalMedicine, March 2025, Elsevier

    Dr Shariful Islam, Alexander Mathioudakis, MD Pilar Rivera Ortega, Dr dan Wootton

  7. Corrigendum to “Prevalence of mental health conditions and brain fog in people with long COVID: A systematic review and meta-analysis” [General Hospital Psychiatry volume 88 (2024)10–22 10.1016/j.genhosppsych.2024.02.009]

    Article • General Hospital Psychiatry, January 2025, Elsevier

    Dr dan Wootton

  8. Exploring the help-seeking journeys for Long Covid from a health inequalities perspective: a qualitative study in England

    Article • December 2024, openRxiv

    Dr dan Wootton

  9. Incidence of diabetes mellitus following hospitalisation for COVID ‐19 in the United Kingdom: A prospective observational study

    Article • Diabetes Obesity and Metabolism, November 2024, Wiley

    MD Pilar Rivera Ortega, Dr dan Wootton

  10. Exploring Histoplasma species seroprevalence and risk factors for seropositivity in The Gambia’s working equid population: Baseline analysis of the Tackling Histoplasmosis project dataset

    Article • Frontiers in Veterinary Science, September 2024, Frontiers

    Dr dan Wootton

  11. Cognitive and psychiatric symptom trajectories 2–3 years after hospital admission for COVID-19: a longitudinal, prospective cohort study in the UK

    Article • The Lancet Psychiatry, September 2024, Elsevier

    MD Pilar Rivera Ortega, Dr Cherie Armour, Dr Peter John Hellyer, Dr dan Wootton

  12. 1-year health outcomes associated with systemic corticosteroids for COVID-19: a longitudinal cohort study

    Article • ERJ Open Research, August 2024, European Respiratory Society (ERS)

    Dr dan Wootton

  13. HAP-FAST: a feasibility study incorporating qualitative, mechanistic and costing sub-studies alongside a randomised pilot trial comparing chest x-ray to low-dose CT scan and empirical antibiotics to antibiotics guided by the BIOFIRE® FILM ARRAY® pneumo...

    Article • BMJ Open, July 2024, BMJ

    Dr dan Wootton

  14. Histoplasma seropositivity and environmental risk factors for exposure in a general population in Upper River Region, The Gambia: A cross-sectional study

    Article • One Health, June 2024, Elsevier

    Dr dan Wootton

  15. Risk of Cardiovascular Events after Acute Exacerbations of Chronic Obstructive Pulmonary Disease in Patients Receiving Long-Term Low-Dose Azithromycin

    Article • American Review of Respiratory Disease, June 2024, Oxford University Press (OUP)

    Dr dan Wootton

  16. Low-dose azithromycin prophylaxis in patients with atrial fibrillation and chronic obstructive pulmonary disease

    Article • Internal and Emergency Medicine, May 2024, Springer Science + Business Media

    Dr dan Wootton

  17. Prevalence of mental health conditions and brain fog in people with long COVID: A systematic review and meta-analysis

    Article • General Hospital Psychiatry, May 2024, Elsevier

    Dr dan Wootton

  18. Author Correction: Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses

    Article • Nature Communications, April 2024, Springer Science + Business Media

    Professor Ahilanandan Dushianthan, Dr Cherie Armour, Dr dan Wootton

  19. Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease

    Article • Nature Immunology, April 2024, Springer Science + Business Media

    Professor Ahilanandan Dushianthan, MD Pilar Rivera Ortega, Dr Cherie Armour, Dr dan Wootton

  20. Barriers to healthcare access and experiences of stigma: Findings from a coproduced Long Covid case‐finding study

    Article • Health Expectations, April 2024, Wiley

    Dr dan Wootton

  21. Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial

    Article • The Lancet Child & Adolescent Health, March 2024, Elsevier

    MD Pilar Rivera Ortega, Alexander Mathioudakis, Dr dan Wootton

  22. Accelerated immune ageing is associated with COVID-19 disease severity

    Article • Immunity & Ageing, January 2024, Springer Science + Business Media

    MD Pilar Rivera Ortega, Trudie Chalder, Dr dan Wootton

  23. Barriers to healthcare access: findings from a co-produced Long Covid case-finding study

    Article • January 2024, openRxiv

    Dr dan Wootton

  24. Effect of second booster vaccinations and prior infection against SARS-CoV-2 in the UK SIREN healthcare worker cohort

    Article • The Lancet Regional Health - Europe, January 2024, Elsevier

    Dr dan Wootton

  25. Residual Lung Abnormality Following COVID-19 Hospitalisation is Characterised by Epithelial Injury

    Article • January 2024, Elsevier

    Dr dan Wootton

  26. Delayed Mucosal Antiviral Responses Despite Robust Peripheral Inflammation in Fatal COVID-19

    Article • The Journal of Infectious Diseases, December 2023, Oxford University Press (OUP)

    Professor Ahilanandan Dushianthan, Dr dan Wootton

  27. Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses

    Article • Nature Communications, December 2023, Springer Science + Business Media

    Professor Ahilanandan Dushianthan, Dr dan Wootton

  28. Cohort Profile: Post-Hospitalisation COVID-19 (PHOSP-COVID) study

    Article • International Journal of Epidemiology, December 2023, Oxford University Press (OUP)

    Dr Cherie Armour, MD Pilar Rivera Ortega, Dr dan Wootton

  29. Large scale phenotyping of long COVID inflammation reveals mechanistic subtypes of disease after COVID-19 hospitalisation

    Article • December 2023, Springer Science + Business Media

    Dr dan Wootton

  30. Clinical trials of pneumonia management assess heterogeneous outcomes and measurement instruments

    Article • Journal of Clinical Epidemiology, December 2023, Elsevier

    Alexander Mathioudakis, Dr dan Wootton

  31. Pathways to care for Long COVID and for long‐term conditions from patients' and clinicians' perspective

    Article • Journal of Evidence-Based Medicine, November 2023, Wiley

    Dr dan Wootton

  32. One year health outcomes associated with systemic corticosteroids for COVID-19: a longitudinal cohort study

    Article • November 2023, openRxiv

    Dr dan Wootton

  33. Long COVID research: an update from the PHOSP-COVID Scientific Summit

    Article • The Lancet Respiratory Medicine, November 2023, Elsevier

    MD Pilar Rivera Ortega, Dr Cherie Armour, Prof. Markus Ralser, Dr dan Wootton

  34. Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study

    Article • The Lancet Respiratory Medicine, November 2023, Elsevier

    MD Pilar Rivera Ortega, Trudie Chalder, Dr Cherie Armour, Prof. Markus Ralser, Mark Philip Cassar, Dr dan Wootton

  35. Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Article • The Lancet Diabetes & Endocrinology, October 2023, Elsevier

    MD Pilar Rivera Ortega, Henry Wu, Alexander Mathioudakis, Dr dan Wootton

  36. Histoplasma Seropositivity in TB Patients in The Gambia: Evidence to Drive Research on a High-Priority Fungal Pathogen

    Article • Open Forum Infectious Diseases, September 2023, Oxford University Press (OUP)

    Dr dan Wootton

  37. Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history

    Article • Nature Communications, August 2023, Springer Science + Business Media

    Dr dan Wootton

  38. Long Covid active case finding study protocol: A co-produced community-based pilot within the STIMULATE-ICP study (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways)

    Article • PLOS One, July 2023, PLOS

    Dr Nisreen A Alwan, Hugh Montgomery, Dr dan Wootton

  39. SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease

    Article • Nature Reports Stem Cells, July 2023, Springer Science + Business Media

    Dr Benjamin Mullish, Dr Stephen P McAdoo, Dr dan Wootton

  40. Prevalence of swallow, communication, voice and cognitive compromise following hospitalisation for COVID-19: the PHOSP-COVID analysis

    Article • BMJ Open Respiratory Research, July 2023, BMJ

    Trudie Chalder, Dr dan Wootton

  41. Large scale phenotyping of long COVID inflammation reveals mechanistic subtypes of disease

    Article • June 2023, openRxiv

    Dr dan Wootton

  42. Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls

    Article • The Lancet Regional Health - Europe, June 2023, Elsevier

    MD Pilar Rivera Ortega, Trudie Chalder, Dr Stephen P McAdoo, Prof. Markus Ralser, Dr dan Wootton

  43. Cohort Profile: Post-hospitalisation COVID-19 study (PHOSP-COVID)

    Article • May 2023, openRxiv

    Dr dan Wootton

  44. Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study

    Article • The Lancet Respiratory Medicine, April 2023, Elsevier

    MD Pilar Rivera Ortega, Trudie Chalder, Dr Stephen P McAdoo, Prof. Markus Ralser, Dr dan Wootton

  45. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

    Article • The Lancet, April 2023, Elsevier

    MD Pilar Rivera Ortega, Salman Razvi, Hugh Montgomery, Alexander Mathioudakis, Dr dan Wootton

  46. The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection

    Article • March 2023, Springer Science + Business Media

    Professor Ahilanandan Dushianthan, Dr Alistair C Darby, Dr dan Wootton

  47. Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study

    Article • EClinicalMedicine, March 2023, Elsevier

    MD Pilar Rivera Ortega, Dr Cherie Armour, Dr Stephen P McAdoo, Prof. Markus Ralser, Dr dan Wootton

  48. Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens

    Article • Med, March 2023, Elsevier

    Dr dan Wootton

  49. Multi-organ impairment and long COVID: a 1-year prospective, longitudinal cohort study

    Article • Journal of the Royal Society of Medicine, February 2023, SAGE Publications

    Dr dan Wootton

  50. Outcome of COVID-19 in hospitalised immunocompromised patients: An analysis of the WHO ISARIC CCP-UK prospective cohort study

    Article • PLoS Medicine, January 2023, PLOS

    Dr dan Wootton

  51. Omicron BA.1/BA.2 infections in triple-vaccinated individuals enhance a diverse repertoire of mucosal and blood immune responses

    Article • January 2023, openRxiv

    Dr dan Wootton

  52. The effects of sleep disturbance on dyspnoea and impaired lung function following COVID-19 hospitalisation: a prospective multi-centre cohort study

    Article • December 2022, Cold Spring Harbor Laboratory Press

    Trudie Chalder, Dr dan Wootton

  53. Residual Lung Abnormalities Following COVID-19 Hospitalization: Interim Analysis of the UKILD Post-COVID Study

    Article • American Review of Respiratory Disease, December 2022, American Thoracic Society

    MD Pilar Rivera Ortega, Dr dan Wootton

  54. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

    Article • EBioMedicine, December 2022, Elsevier

    MD Pilar Rivera Ortega, Mark Philip Cassar, Prof. Markus Ralser, Professor Ahilanandan Dushianthan, Dr Cherie Armour, Dr Stephen P McAdoo, Dr dan Wootton

  55. STIMULATE-ICP-Delphi study to inform integrated care pathways for Long COVID.

    Article • PLOS One, November 2022, PLOS

    Christina Van der Feltz-Cornelis, Hugh Montgomery, Dr dan Wootton

  56. Viral Coinfections in Hospitalized Coronavirus Disease 2019 Patients Recruited to the International Severe Acute Respiratory and Emerging Infections Consortium WHO Clinical Characterisation Protocol UK Study

    Article • Open Forum Infectious Diseases, October 2022, Oxford University Press (OUP)

    Professor Ahilanandan Dushianthan, Dr dan Wootton

  57. Nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

    Article • September 2022, openRxiv

    Dr dan Wootton

  58. Long Covid active case finding: a co-produced community-based pilot within the STIMULATE-ICP study (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways)

    Article • August 2022, openRxiv

    Dr dan Wootton

  59. STIMULATE-ICP-CAREINEQUAL (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways) study protocol: Defining usual care and examining inequalities in Long Covid support

    Article • PLOS One, August 2022, PLOS

    Hugh Montgomery, Dr dan Wootton

  60. Outcome of COVID-19 in hospitalised immunocompromised patients: an analysis of the WHO ISARIC CCP-UK prospective cohort study

    Article • August 2022, openRxiv

    Dr dan Wootton

  61. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study

    Article • The Lancet Respiratory Medicine, August 2022, Elsevier

    Dr Omer Elneima, MD Pilar Rivera Ortega, Mark Philip Cassar, Prof Nicholas Hart, Prof. Markus Ralser, Trudie Chalder, Dr Cherie Armour, Dr Stephen P McAdoo, Dr dan Wootton

  62. Device-assessed sleep and physical activity in individuals recovering from a hospital admission for COVID-19: a multicentre study

    Article • International Journal of Behavioral Nutrition and Physical Activity, July 2022, Springer Science + Business Media

    Dr Omer Elneima, Dr dan Wootton

  63. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

    Article • The Lancet, July 2022, Elsevier

    MD Pilar Rivera Ortega, Salman Razvi, Hugh Montgomery, Alexander Mathioudakis, Dr dan Wootton

  64. Evolution of long-term vaccine induced and hybrid immunity in healthcare workers after different COVID-19 vaccination regimens: a longitudinal observational cohort study

    Article • June 2022, openRxiv

    Dr dan Wootton

  65. STIMULATE-ICP-CAREINEQUAL - Defining usual care and examining inequalities in Long Covid support: protocol for a mixed-methods study (part of STIMULATE-ICP: Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Tran...

    Article • May 2022, openRxiv

    Dr dan Wootton

  66. Comparison of two T-cell assays to evaluate T-cell responses to SARS-CoV-2 following vaccination in naïve and convalescent healthcare workers

    Article • Clinical & Experimental Immunology, May 2022, Oxford University Press (OUP)

    Dr dan Wootton

  67. STIMULATE-ICP-Delphi (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways Delphi): Study protocol

    Article • April 2022, Cold Spring Harbor Laboratory Press

    Dr William D Strain, Dr dan Wootton

  68. Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study

    Article • The Lancet Digital Health, April 2022, Elsevier

    Professor Ahilanandan Dushianthan, Dr dan Wootton

  69. Multi-organ impairment and Long COVID: a 1-year prospective, longitudinal cohort study

    Article • March 2022, openRxiv

    Dr dan Wootton

  70. Interstitial lung damage following COVID-19 hospitalisation: an interim analysis of the UKILD Post-COVID study

    Article • March 2022, openRxiv

    Dr dan Wootton

  71. Comparison of two T cell assays to evaluate T cell responses to SARS-CoV-2 following vaccination in naïve and convalescent healthcare workers

    Article • February 2022, openRxiv

    Dr dan Wootton

  72. Device-assessed sleep and physical activity in individuals recovering from a hospital admission for COVID-19: a prospective, multicentre study

    Article • February 2022, openRxiv

    Dr dan Wootton

  73. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

    Article • Cell, February 2022, Elsevier

    Michael Olanipekun, Professor Ahilanandan Dushianthan, Dr dan Wootton

  74. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Article • The Lancet, February 2022, Elsevier

    MD Pilar Rivera Ortega, Salman Razvi, Hugh Montgomery, Alexander Mathioudakis, Dr dan Wootton

  75. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Article • The Lancet, January 2022, Elsevier

    Dr Ryan Malcolm Hum, MD Pilar Rivera Ortega, Salman Razvi, Hugh Montgomery, Dr Marlies Ostermann, Dr dan Wootton

  76. T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study

    Article • The Lancet Microbe, January 2022, Elsevier

    Professor William s James, Dr dan Wootton

  77. Clinical characteristics with inflammation profiling of Long-COVID and association with one-year recovery following hospitalisation in the UK: a prospective observational study

    Article • December 2021, Cold Spring Harbor Laboratory Press

    Prof Nicholas Hart, Dr dan Wootton

  78. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study

    Article • The Lancet Respiratory Medicine, November 2021, Elsevier

    MD Pilar Rivera Ortega, Dr Omer Elneima, Prof Nicholas Hart, Prof. Markus Ralser, Trudie Chalder, Dr Stephen P McAdoo, David Baldwin, Dr dan Wootton

  79. The impact of viral mutations on recognition by SARS-CoV-2 specific T cells

    Article • iScience, November 2021, Elsevier

    Michael Olanipekun, Professor Ahilanandan Dushianthan, Dr Marlies Ostermann, Dr dan Wootton

  80. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine

    Article • Cell, November 2021, Elsevier

    Dr dan Wootton

  81. Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID)

    Article • BMJ Open Respiratory Research, September 2021, BMJ

    MD Pilar Rivera Ortega, Dr dan Wootton

  82. Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study

    Article • The Lancet Microbe, August 2021, Elsevier

    Professor Ahilanandan Dushianthan, Dr dan Wootton

  83. Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study

    Article • The Lancet, July 2021, Elsevier

    Michael Olanipekun, Professor Ahilanandan Dushianthan, Dr Marlies Ostermann, Dr dan Wootton

  84. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

    Article • The Lancet, May 2021, Elsevier

    Dr Ryan Malcolm Hum, MD Pilar Rivera Ortega, Salman Razvi, Hugh Montgomery, avinash aujayeb, Dr dan Wootton

  85. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Article • The Lancet, May 2021, Elsevier

    Dr Ryan Malcolm Hum, MD Pilar Rivera Ortega, Salman Razvi, Hugh Montgomery, avinash aujayeb, Henry Wu, Dr dan Wootton

  86. A rapid assessment of wastewater for genomic surveillance of SARS-CoV-2 variants at sewershed scale in Louisville, KY

    Article • March 2021, openRxiv

    Dr dan Wootton

  87. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study

    Article • BMJ Open, March 2021, BMJ

    Dr dan Wootton

  88. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Article • The Lancet, February 2021, Elsevier

    MD Pilar Rivera Ortega, Dr Ryan Malcolm Hum, Dr Omer Elneima, Salman Razvi, Henry Wu, Dr dan Wootton

  89. Prognostic Indicators and Outcomes of Hospitalised COVID-19 Patients with Neurological Disease: A Systematic Review and Individual Patient Data Meta-Analysis

    Article • SSRN Electronic Journal, January 2021, Elsevier

    Catrin Tudur Smith, Nicola Desmond, Dr dan Wootton

  90. Co-Infections, Secondary Infections, and Antimicrobial Usage in Hospitalised Patients with COVID-19 from the ISARIC WHO CCP-UK Study: A Prospective, Multicentre Cohort Study

    Article • SSRN Electronic Journal, January 2021, Elsevier

    Dr dan Wootton

  91. Utility of established prognostic scores in COVID-19 hospital admissions: multicentre prospective evaluation of CURB-65, NEWS2 and qSOFA

    Article • BMJ Open Respiratory Research, December 2020, BMJ

    Dr dan Wootton

  92. The utility of established prognostic scores in COVID-19 hospital admissions: a multi-centre prospective evaluation of CURB-65, NEWS2, and qSOFA

    Article • July 2020, openRxiv

    Dr dan Wootton

  93. The challenge of antimicrobial prescribing for hospital-acquired pneumonia

    Article • Journal of Hospital Infection, February 2020, Elsevier

    Dr dan Wootton

  94. Antimicrobial prescribing for hospital-acquired pneumonia

    Article • British Journal of Hospital Medicine, January 2020, Mark Allen Group

    Dr dan Wootton

  95. Community‐acquired pneumonia due to drug‐resistantEnterobacteriaceae: A global perspective

    Article • Respirology, October 2019, Wiley

    Dr dan Wootton

  96. A Haemophilus sp. dominates the microbiota of sputum from UK adults with non-severe community acquired pneumonia and chronic lung disease

    Article • Scientific Reports, February 2019, Springer Science + Business Media

    Dr dan Wootton

  97. Quantification of Efferocytosis by Single-cell Fluorescence Microscopy

    Article • Journal of Visualized Experiments, August 2018, MyJove Corporation

    Dr dan Wootton

  98. A longitudinal modelling study estimates acute symptoms of community acquired pneumonia recover to baseline by 10 days

    Article • European Respiratory Journal, June 2017, European Respiratory Society (ERS)

    Dr dan Wootton

  99. Recovery from pneumonia requires efferocytosis which is impaired in smokers and those with low body mass index and enhanced by statins

    Article • Thorax, July 2016, BMJ

    Dr dan Wootton

  100. Correction

    Article • Thorax, February 2016, BMJ

    Dr dan Wootton

  101. Household Air Pollution Causes Dose-Dependent Inflammation and Altered Phagocytosis in Human Macrophages

    Article • American Journal of Respiratory Cell and Molecular Biology, May 2015, Oxford University Press (OUP)

    Dr dan Wootton

  102. Blinded randomised controlled trial of low-dose Adjuvant Steroids in Adults admitted to hospital with Pandemic influenza (ASAP): a trial ‘in hibernation’, ready for rapid activation

    Article • Health Technology Assessment, February 2015, National Institute for Health Research

    Professor Jonathan Stafford Nguyen-Van-Tam, Dr dan Wootton

  103. The diagnosis of pneumonia requires a chest radiograph (x-ray) – yes, no or sometimes?

    Article • Pneumonia, June 2014, Springer Science + Business Media

    Dr dan Wootton

  104. Bronchoalveolar Lavage (BAL) for Research; Obtaining Adequate Sample Yield

    Article • Journal of Visualized Experiments, March 2014, MyJove Corporation

    Dr dan Wootton

  105. The pathophysiology of pneumococcal pneumonia

    Article • March 2014, European Respiratory Society (ERS)

    Dr dan Wootton

  106. Feasibility study for early supported discharge in adults with respiratory infection in the UK

    Article • BMC Pulmonary Medicine, February 2014, Springer Science + Business Media

    Dr dan Wootton

  107. Supported home-care schemes: the key to increasing outpatient care?

    Article • European Respiratory Journal, January 2012, European Respiratory Society (ERS)

    Dr dan Wootton

  108. Using the BTS CAP audit to evaluate local data

    Article • Thorax, September 2011, BMJ

    Dr dan Wootton

  109. Pharmacokinetics of chlorproguanil, dapsone, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria

    Article • European Journal of Clinical Pharmacology, June 2009, Springer Science + Business Media

    Dr dan Wootton

  110. Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi

    Article • Malaria Journal, January 2009, Springer Science + Business Media

    Dr dan Wootton

  111. Open-Label Comparative Clinical Study of Chlorproguanil−Dapsone Fixed Dose Combination (Lapdap™) Alone or with Three Different Doses of Artesunate for Uncomplicated Plasmodium falciparum Malaria

    Article • PLOS One, March 2008, PLOS

    Dr dan Wootton

  112. Malaria: clinical features and recommended management

    Article • Prescriber, November 2006, Wiley

    Dr dan Wootton